$918.99 Million in Sales Expected for Cabot Co. (NYSE:CBT) This Quarter

Wall Street analysts predict that Cabot Co. (NYSE:CBTGet Rating) will report sales of $918.99 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Cabot’s earnings, with estimates ranging from $880.20 million to $957.77 million. Cabot reported sales of $842.00 million during the same quarter last year, which indicates a positive year-over-year growth rate of 9.1%. The company is scheduled to issue its next earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Cabot will report full year sales of $3.67 billion for the current fiscal year, with estimates ranging from $3.51 billion to $3.77 billion. For the next financial year, analysts expect that the company will post sales of $3.76 billion, with estimates ranging from $3.62 billion to $3.85 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover Cabot.

Cabot (NYSE:CBTGet Rating) last posted its quarterly earnings results on Monday, January 31st. The specialty chemicals company reported $1.29 EPS for the quarter, beating the consensus estimate of $1.06 by $0.23. Cabot had a return on equity of 28.88% and a net margin of 2.78%. The company had revenue of $968.00 million during the quarter, compared to analysts’ expectations of $815.24 million. During the same quarter in the previous year, the business earned $1.18 EPS.

A number of analysts have recently issued reports on the company. TheStreet cut Cabot from a “b” rating to a “c+” rating in a report on Monday, January 31st. UBS Group upped their price target on Cabot from $71.00 to $85.00 in a report on Wednesday, February 16th. StockNews.com initiated coverage on Cabot in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Zacks Investment Research cut Cabot from a “buy” rating to a “hold” rating and set a $71.00 price target for the company. in a report on Tuesday, April 5th. Three equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $73.00.

Shares of NYSE:CBT opened at $67.65 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.80 and a current ratio of 1.21. Cabot has a 1 year low of $47.59 and a 1 year high of $74.87. The stock has a market capitalization of $3.83 billion, a P/E ratio of 39.56 and a beta of 1.44. The stock has a 50-day simple moving average of $70.07 and a 200-day simple moving average of $61.42.

In related news, SVP Hobart Kalkstein sold 11,805 shares of the company’s stock in a transaction that occurred on Wednesday, February 16th. The stock was sold at an average price of $73.50, for a total transaction of $867,667.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 2.20% of the company’s stock.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its position in shares of Cabot by 3.2% during the 4th quarter. BlackRock Inc. now owns 6,244,761 shares of the specialty chemicals company’s stock valued at $350,955,000 after acquiring an additional 194,544 shares in the last quarter. Fuller & Thaler Asset Management Inc. raised its position in shares of Cabot by 1.3% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 3,472,952 shares of the specialty chemicals company’s stock valued at $195,180,000 after acquiring an additional 43,804 shares in the last quarter. Earnest Partners LLC grew its stake in Cabot by 1.0% during the 4th quarter. Earnest Partners LLC now owns 3,086,614 shares of the specialty chemicals company’s stock worth $173,468,000 after buying an additional 31,206 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Cabot by 1,309.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,077,204 shares of the specialty chemicals company’s stock worth $172,939,000 after buying an additional 2,858,841 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in Cabot by 3.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,499,126 shares of the specialty chemicals company’s stock worth $125,256,000 after buying an additional 93,211 shares during the last quarter. 90.85% of the stock is currently owned by institutional investors and hedge funds.

About Cabot (Get Rating)

Cabot Corporation operates as a specialty chemicals and performance materials company. It operates through three segments: Reinforcement Materials, Performance Chemicals, and Purification Solutions. The company offers reinforcing carbons used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites.

Featured Articles

Get a free copy of the Zacks research report on Cabot (CBT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cabot (NYSE:CBT)

Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.